Article in The Journal of infectious diseases, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Alex RinehartViiV Healthcare, Durham, North Carolina, USA.
Jon W CollinsViiV Healthcare, Durham, North Carolina, USA.
James F RooneyGilead Sciences, Foster City, California, USA.
Lydia Soto TorresNIH Division of AIDS, Bethesda, Maryland, USA.
Paul RichardsonJohn Hopkins School of Medicine, John Hopkins University, Baltimore, Maryland, USA.ORCID 0000-0003-1488-3054
Suwat ChariyalerstsakDepartment of Community Medicine, Chang Mai University, Chang Mai, Thailand.ORCID 0000-0002-4998-7841
Jose Valdez Ramalho MadrugaSecretarial of Health, Sao Paulo, Brazil.
Christopher B HurtInstitute for Global Health and Infectious Diseases, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.ORCID 0000-0003-3290-8200
Manya MagnusMilken Institute School of Public Health, George Washington University, Washington DC, USA.ORCID 0000-0002-6359-987X
Ian FrankDivision of Infectious Diseases, University of Pennsylvania, Philadelphia, Pennsylvania, USA.
Marybeth McCauleyFamily Health International (FHI 360), Washington, DC, USA.
Beatriz GrinsztejnEvandro Chagas National Institute of Infectious Diseases-Oswaldo Cruz Foundation, Rio ds Janeiro, Brazil.
Raphael J LandovitzCARE Center, University of California Los Angeles, Los Angeles, California, USA.ORCID 0000-0002-1442-714X
Funding
LOC: HIV Prevention Trials NetworkUM1AI068619 · NIAID · FAMILY HEALTH INTERNATIONAL · PI MYRON Scott COHEN, Sinead Delany-Moretlwe · 2011 to 2026
$779.5M
SDMC: HPTN 084 Pregnancy SupplementUM1AI068617 · NIAID · FRED HUTCHINSON CANCER RESEARCH CENTER · PI Elizabeth Renata Brown, Deborah J Donnell · 2011 to 2026
$204.9M
LC: HIV Prevention Trials Network - Laboratory Support for the SARS-CoV-2 Seroprevalence Study (CoVPN 5002)UM1AI068613 · NIAID · JOHNS HOPKINS UNIVERSITY · PI SUSAN H ESHLEMAN, Mark A Marzinke · 2011 to 2026
$100.2M
Virus & Reservoirs CoreP30AI045008 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI ROBERT GROSS · 1999 to 2026
$78.6M
UCLA AIDS Prevention and Treatment Clinical Trials UnitUM1AI069424 · NIAID · UNIVERSITY OF CALIFORNIA LOS ANGELES · PI Judith S. Currier, RAPHAEL J LANDOVITZ · 2012 to 2026
$51.8M
University of Pennsylvania HIV Clinical Trials UnitUM1AI069534 · NIAID · UNIVERSITY OF PENNSYLVANIA · PI Ian Frank, PABLO TEBAS · 2012 to 2026
$33.0M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)UM1AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI BEATRIZ GRINSZTEJN · 2012 to 2026
$26.3M
The FIOCRUZ Therapeutic and Prevention HIV/AIDS Clinical Trials Unit (FioTrials)U01AI069476 · NIAID · FUNDACAO OSWALDO CRUZ · PI GRINSZTEJN, BEATRIZ · 2008 to 2011
$14.0M
The District of Columbia Clinical Trials Unit (DC CTU)UM1AI154466 · NIAID · GEORGE WASHINGTON UNIVERSITY · PI Sarah Henn, Manya Magnus · 2021 to 2026
$12.5M
Gilead SciencesHIV Prevention Trials Network [HPTN] Leadership and Operations Center UM1AI068617HPTN Laboratory CenterHPTN Statistical and Data Management Center UM1AI068613National Institute of Allergy and Infectious DiseasesNIAID NIH HHS P30 AI045008NIAID NIH HHS U01 AI069476NIAID NIH HHS UM1 AI068613NIAID NIH HHS UM1 AI068617NIAID NIH HHS UM1 AI069424NIAID NIH HHS UM1 AI069476NIAID NIH HHS UM1 AI069534NIAID NIH HHS UM1 AI154466NIDA NIH HHS UM1AI068619NIH HHSNIMH NIH HHSODCDC CDC HHSViiV Healthcare
6 · The paper itself
Abstract
backgroundThe HIV Prevention Trials Network (HPTN) 083 Trial demonstrated the superiority of long-acting, injectable cabotegravir (CAB) over daily oral tenofovir disoproxil fumarate/emtricitabine (TDF/FTC) for HIV pre-exposure prophylaxis among cisgender men (MSM) and transgender women (TGW) who have sex with men. Plasma CAB concentrations associated with HIV protection in humans are unknown.
methodsWe conducted a nested case-control study to investigate the association between plasma CAB concentrations and HIV risk. Plasma CAB concentrations were estimated for participants with confirmed HIV and for HIV-negative controls, who were matched on region, gender, and race. The window of HIV acquisition for cases was defined as the time between the last HIV-negative visit and the first HIV-positive visit; this window was used to evaluate CAB exposure for cases and their matched controls. Participants were categorized by the minimum estimated CAB concentration (CABmin) during this window relative to the protein-adjusted 90% CAB inhibitory concentration (1× PA-IC90) and 4× PA-IC90. HIV risk was modeled using conditional logistic regression.
resultsPlasma CABmin was ≥4× PA-IC90 in 26% of HIV-positive cases, compared with 76% of matched controls. Plasma CABmin ≥4× PA-IC90 was associated with a 93% reduction in risk of HIV acquisition compared with CABmin <1× PA-IC90 (95% CI: 76%, 98%, P < .001). CABmin between 1× and 4× PA-IC90 had an estimated risk reduction of 79% compared with CABmin <1× PA-IC90 (95% CI: -19%, 96%, P = .07).
conclusionsConsistent plasma CAB concentrations ≥4× PA-IC90 were estimated to provide 93% protection against HIV in MSM and TGW.
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Estimation of Prevention-Effective CAB-LA Concentrations Among Men Who Have Sex With Men (MSM) and Transgender Women (TGW) in HPTN 083. · full record | OpenQuestion